Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Immunologic Impact in CRSwNP and Asthma Post-ESS
NCT06556264Phase 4Not yet recruiting
- Sponsor
- Dr. Andrew Thamboo
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, sponsored by Dr. Andrew Thamboo. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)asthma
Beyond the preview
Go deeper on NCT06556264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556264.